EnVivo Pharmaceuticals Inc. avoided a geographical bias that may have tripped up clinical studies of another player's nicotinic acetylcholine receptor alpha 7 agonist and is now the only company to report positive Phase II results in not one but two CNS indications.

The company plans to start Phase III testing in schizophrenia this fall and in Alzheimer's disease in 2013.